Since Novartis' COX-2 inhibitor lumiracoxib [`Prexige'] has failed to demonstrate features differentiating it from the class leader celecoxib [`Celebrex; Pfizer/Pharmacia'], it could have limited market success

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 403, 2003-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Clinical pharmacology of celecoxib, a COX-2 selective inhibitor

By Antoniou Katerina   Malamas Michael   Drosos Alexandros A  

Expert Opinion on Pharmacotherapy, Vol. 8, Iss. 11, 2007-08 ,pp. : 1719-1732

Informa Healthcare

Access to resources Recommend Favorite

Colon-specific delivery of celecoxib is a potential strategy to improve toxicological and pharmacological properties of the selective Cox-2 inhibitor: implication in treatment of familiar adenomatous polyposis

By Lee Yonghyun   Kim Hyunjeong   Kim Wooseong   Yoon Jeong-Hyun   Jeong Seong Hoon   Jung Yunjin  

Journal of Drug Targeting, Vol. 20, Iss. 6, 2012-07 ,pp. : 524-534

Informa Healthcare

Access to resources Recommend Favorite

Celecoxib is a CYP1A2 inhibitor in vitro but not in vivo

By Karjalainen Marjo   Neuvonen Pertti   Backman Janne  

European Journal of Clinical Pharmacology, Vol. 64, Iss. 5, 2008-05 ,pp. : 511-519

Springer Publishing Company

Access to resources Recommend Favorite

COX-2 Inhibitors Celecoxib and Parecoxib: Valuable Options for Postoperative Pain Management

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 3, 2007-02 ,pp. : 235-249

Bentham Science Publishers

Access to resources Recommend Favorite